CD274 and neoplasm: Although biomarkers such as PD‐L1, tumor mutational burden (TMB), mismatch repair (MMR)/microsatellite instability (MSI) have been shown to be promising,6, 7, 8 there is still not a perfect biomarker to select patients to receive PD‐1/PD‐L1 inhibitors accurately.